Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!

Description of the medicine: Intron-A (Intron-A)

INTRON-A (Intron-A).

Recombinant interferon alpha-2b synthesized in E. coli culture.

Has antiviral, immunomodulating and antitumor effect.

Applied with multiple myeloma, Kaposi's sarcoma, hairy cell leukemia and other oncological diseases, as well as chronic hepatitis B, C and D, HIV infection.

Assign usually subcutaneously, intramuscularly, sometimes intravenously, if necessary - intracavitary.

In chronic hepatitis B injected subcutaneously or intramuscularly at 5 000 000 IU daily or 10 000 000 IU 3 times a week for at least 16 weeks.

In chronic hepatitis C, subcutaneously 3,000,000 IU is administered 3 times a week for at least 18 months.

In chronic hepatitis D, subcutaneously injected 5,000,000 IU / m 2 daily or 3 times a week for 3-4 months or more.

In chronic myelogenous leukemia, 4,000,000 to 5,000,000 IU / m 2 per day are prescribed, maintaining doses of 500,000 to 10,000,000 IU / m 2 .

With multiple myeloma, 3,000,000 - 5,000,000 IU are administered 2 times a week during the entire induction therapy period.

With Kaposi's sarcoma, 30,000,000 IU / m 2 daily or 3 times a week are used for HIV infection.

In case of cancer, kidneys are prescribed 20,000,000 IU / m 2 daily for 3 months or more.

In ovarian cancer, 50,000,000 IU of intraperitoneal injection is administered intraperitoneally for 16 weeks.

When malignant melanoma is prescribed intravenously to 20,000,000 IU / m 2 5 times a week from 4 weeks to 2 years.

When bladder cancer is administered intravesical 30 000 000 - 50 000 000 IU once a week for 8-12 weeks.

Solutions are prepared immediately prior to administration.

When using the drug, various side effects are possible: nausea, dizziness, fever, diarrhea, myalgia, arterial hypotension, etc .; At course treatment probably granulotsitopenia, thrombocytopenia, a violation of the liver, stomatitis, etc.

Form release: lyophilized powder for injection solutions in vials of 3,000,000, 5,000,000, 10,000,000 and 30,000,000 IU.

Storage: List B. At temperatures from +2 to +8 ° C.